COVID-19 Vaccine-Induced Myocarditis: A Systemic Review and Literature Search

Zahid Khan 1,2,3, Umesh Kumar Pabani 4, Amresh Gul 5, Syed Aun Muhammad 6, Yousif Yousif 4, Mohammed Abumedian 7, Ola Elmahdi 8, Animesh Gupta 9,10

1. Acute Medicine, Med and South Essex NHS Foundation Trust, Southend on Sea, GBR 2. Cardiology and General Medicine, Barking, Havering and Redbridge University Hospitals NHS Trust, London, GBR 5. Cardiology, Royal Free Hospital, London, GBR 4. Internal Medicine, Barking, Havering and Redbridge University Hospitals NHS Trust, London, GBR 5. General Practice, Starcare Hospital, Duqm, OMN 6. Cardiology, Med and South Essex NHS Foundation Trust, Southend on Sea, GBR 7. Geriatrics, Barking, Havering and Redbridge University Hospitals NHS Trust, London, GBR 8. Internal Medicine, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, GBR 9. Acute Internal Medicine, Southend University Hospital, Southend on Sea, GBR 10. Acute Internal Medicine and Intensive Care, Barking, Havering and Redbridge University Hospitals NHS Trust, London, GBR

Corresponding author: Zahid Khan, drzahid1985@yahoo.com

Abstract

Myocarditis is one of the complications reported with COVID-19 vaccines, particularly both Pfizer-BioNTech and Moderna vaccines. Most of the published data about this association come from case reports and series. Integrating the geographical data, clinical manifestations, and outcomes is therefore important in patients with myocarditis to better understand the disease. A thorough literature search was conducted in Cochrane library, PubMed, ScienceDirect, and Google Scholar for published literature till 30 March 2022. We identified 26 patients eligible from 29 studies; the data were pooled from these qualifying case reports and case series. Around 94% of patients were male in this study, the median age for onset of myocarditis was 22 years and 85% developed symptoms after the second dose. The median time of admission for patients to hospitals post-vaccination was three days and chest pain was the most common presenting symptom in these patients. Most patients had elevated troponin on admission and about 90% of patients had cardiac magnetic resonance imaging (CMR) that showed late gadolinium enhancement. All patients admitted with myocarditis were discharged home after a median stay of four days. Results from this current analysis show that post-mRNA vaccination myocarditis is mainly seen in young males after the second dose of vaccination. The pathophysiology of vaccine-induced myocarditis is not entirely clear and late gadolinium enhancement is a common finding on CMR in these patients that may indicate myocardial fibrosis or necrosis. Prognosis remains good and all patients recovered from myocarditis, however further studies are advisable to assess long-term prognosis of myocarditis.

Keywords: 12-lead ecg, pericardial diseases, cardiac chest pain, cardiac magnetic resonance imaging, cardiac troponin, post vaccination myocarditis, covid-induced myocarditis, covid 19 vaccine complication, covid vaccine-induced myocarditis, covid and myocarditis

Introduction And Background

Myocarditis is inflammation of the myocardium that can occur due to a variety of reasons, with a viral infection being the most common cause for it. Myocarditis and its related complications are believed to be largely immune-mediated [1]. The most common presentation of myocarditis is with chest pain, which can result from associated pericarditis or coronary artery spasm [2,3]. Pericarditis commonly presents with sharp, retrosternal chest pain that is exacerbated by coughing, breathing, and lying in the supine position and is relieved by sitting or leaning forward [2]. Myocarditis can affect people of all ages but typically individuals between ages 20 and 50 and diagnosis can be challenging due to the significant variation in the clinical presentation [4]. Most patients present with chest pain as the main presenting complaint (85-95% of cases), fever (65%), and dyspnoea (19–49%) of patients [4,5]. It is however important to differentiate myocarditis from acute coronary syndrome and pericarditis as they can present with similar clinical features [5]. About 80% of patients with acute myocarditis have a history of a preceding viral cold, respiratory or gastrointestinal problems [1].

Myocarditis can be classified into acute, fulminant, subacute, and chronic forms depending on the onset of symptoms [4,6]. Acute myocarditis presents within < 1 month of onset of symptoms and diagnosis whereas fulminant myocarditis is associated with cardiogenic shock and requires inotropes or mechanical circulatory support and is a severe form of acute myocarditis that evolves rapidly. Subacute myocarditis present between one to three months after the onset of symptoms and diagnosis whereas in the case of chronic myocarditis, symptoms persist for over a month representing a kind of chronic inflammatory cardiomyopathy [4,6].

Based on the International Classification of Disease (ICD), there were 32 cases of myocarditis per 100'000
patients reported by the Global Burden of Disease study based on the hospital discharge summaries between 1990 and 2013 [6]. The National Health Services (NHS) England data between 1998 and 2017 reported 12,1929 admissions with myocarditis which accounts for 0.04% or 36.5 per 100,000 admissions and approximately two-thirds of these patients were men and the median age was 33 years for men and 46 years for women [7]. The median length of hospital stay for both genders was 4.2 days and the number of admissions is most likely underreported. The data also showed an increasing burden of hospitalization with the disease and there was an 88% increase in admission with myocarditis over the study period compared to a 57% increase in all cardiology admissions [7]. The study also reported a higher incidence of myocarditis cases in winter and was reported as 27% in London and 16% in the Southeast even after adjusting for the regional population differences. Around 20% of mortality was due to non-ischaemic dilated cardiomyopathy and all-cause mortality was 4.16 in the last completed year of data.

COVID-19, caused by coronavirus SARS-CoV-2, led to a worldwide pandemic and a public health emergency. Prodigious immunization campaigns have been initiated throughout the world as per the World Health Organization (WHO) recommendations. This has led to the use of several types of coronavirus vaccines. These include mRNA-based vaccines, inactivated whole viral vaccines, and recombinant adeno viral vector vaccines [3,4]. The accelerated spread of the virus, as well as the unfortunate significant mortality associated with its replication, led to the emergency use of COVID-19 vaccines; the emergency approval of vaccines being against the normal standard protocol of multiple clinical trials taking place to prove the safety of the vaccines. This led to several mild to moderate and serious side effects that have been studied extensively. Few systematic reviews have been published in the past to describe the key characteristics of patients developing COVID-19 myocarditis after receiving vaccinations against the disease. It is important to mention that the most common vaccines received by patients were Pfizer, Moderna, and AstraZeneca vaccines [7,8]. A major side effect reported was myocarditis associated with these vaccines [9]. Myocarditis was more common in patients who received the COVID-19 mRNA vaccine as compared to the non-mRNA vaccine and was also higher in patients who received the second dose of the vaccine. It was also reported to be more common in males and in patients aged 16–39 years [9,10]. The aim of this systemic review is to assess various risk factors and the association of these vaccines with myocarditis.

The study is registered with PROSPERO under registration number CRD42022341932.

**Review Methodology**

Reporting items for systematic reviews and meta-analyses (PRISMA) protocol was used to search for studies. An electronic literature search was performed on Google Scholar, PubMed, Cochrane library and ScienceDirect. PRISMA allowed for a more systemic approach in order to identify articles for inclusion in the study. Various search terminologies were used for the literature search, including 'Covid 19 vaccine and myocarditis', 'COVID-19 vaccine side effects', 'myocarditis, Covid 19 and myocarditis', 'AstraZeneca vaccine and myocarditis', 'Pfizer vaccine and myocarditis', Moderna vaccine and myocarditis', 'myocarditis and pericarditis', 'COVID-19 myocarditis', 'vaccine-induced myocarditis', and 'Covid 19 vaccine and myopericarditis'. The article search was undertaken in April 2022 and a total of 19,742 articles were found through a structured search. An additional 20 articles were found through a Google search. A total of 11,350 articles were left after removing duplicate articles and articles that were not available or were not in the English language. A further 10,155 articles were removed for not meeting the inclusion criteria. As a result, 1,195 articles were screened for eligibility and 1,169 articles were removed for not providing enough information. Finally, 29 articles were included in the systemic review as shown in the PRISMA chart (Figure 1) which were relevant to our study.
FIGURE 1: shows PRISMA 2020 flow chart for the systemic review

Table 1 shows the regular and MeSH keywords used for the literature search.

| Search           | Keywords                                                                                                                                 |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Regular Keywords | Covid 19 vaccine, Myocarditis, Myopericarditis, covid 19 vaccine side effects, Pfizer vaccine, Moderna vaccine, AstraZeneca vaccine, myopericarditis, pericarditis |
| MeSH keywords    | Covid 19 vaccine and myocarditis, COVID-19 vaccine side effects, myocarditis, Covid 19 and myocarditis, AstraZeneca vaccine and myocarditis, Pfizer vaccine and myocarditis, Moderna vaccine and myocarditis, myocarditis, and pericarditis, myopericarditis, COVID-19 myocarditis, vaccine induced myocarditis, Covid 19 vaccine and myopericarditis |

TABLE 1: shows regular and mesh key words used for literature search

Methods

Eligibility Criteria

Inclusion and exclusion criteria were determined and accordingly, articles were assessed. Approximately 50 studies met the criteria, however, after removing duplicate articles, only 29 articles were finally included in the systemic review. The inclusion and exclusion criteria are described below.

Inclusion Criteria

The inclusion criteria were: (1) Patients should have received the COVID-19 vaccination within the last two months; (2) patients should have elevated troponin and echocardiographic/cardiac magnetic resonance imaging findings suggestive of myocarditis; (3) patients should not have had a COVID-19 infection in the preceding month; (4) articles should be written in English; (5) articles should be available through institutional access or be free; and (6), patients should be older than 14 years old.

Exclusion Criteria

The exclusion criteria were: 1 - Studies in which patients did not have the COVID-19 vaccine within the last two months prior to developing Myocarditis. 2 - Studies in which patients had the COVID-19 vaccine within one month of having a COVID-19 infection. 3 - Studies in which patients did not have an echocardiogram, troponin, coronary angiogram +/- CMR to confirm the diagnosis of myocarditis. 4 - Studies in which patients were under 14 years of age. 5 - Studies in which patients had a diagnosis of myopericarditis. 6 - Articles that were not in English and were not accessible through institutional access or were not free.
Study Selection and Data Extraction

All peer-reviewed published studies that included patients above the age of 14 who developed myocarditis following any type of COVID-19 vaccine (mRNA, viral vector, and protein subunit) were included. Review articles, editorials, preprints, and original articles that reported side effects of vaccination but did not discuss myocarditis specifically were excluded.

Data Collection Process and Data Items

The data were extracted independently by two authors using standardized data extraction forms. Data points collected included age, gender, type of vaccination, clinical features, number of days following a vaccine that the symptoms occurred, outcome, laboratory values, methods of diagnosis, and results on an Excel sheet (Microsoft Corporation, Redmond, WA).

Study Analysis

Patient demographic characteristics, disease manifestations, and causes were summarized descriptively.

Results

The results of 29 studies are described below in Table 2. The summaries are pooled together in Table 3.

| Author                      | No. of patients | Male (%) | Age (years) | Hospital presentation (days after vaccination) | Symptoms reported | EKG changes                                                                 | MRI findings                                                                 | Anti-inflammatory treatment used | Previous comorbidities                                                                 |
|-----------------------------|-----------------|----------|-------------|-------------------------------------------------|-------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------|----------------------------------------------------------------------------------------|
| Montgomery et al. 2021 [11] | 23              | 100      | 25          | 4                                               | Chest pain at rest | ST-segment elevations, or T-wave inversions, non-specific T waves and ST-segment changes | Subepicardial LGE and/or focal myocardial oedema                               | No                              | No                                                                                      |
| Garcia et al. 2021 [12]     | 1               | 100      | 39          | 1                                               | Intermitent chest and interscapular pain | Sinus tachycardia, narrow QRS complex, diffuse ST-elevation | Oedema on T2-weighted short tau inversion recovery sequences and subepicardial enhancement in the lateral mediastinal region | Yes                             | Asthma, atrial fibrillation and hypothyroidism                                      |
| Kim et al. 2021 [13]        | 7               | 85       | 23          | 5                                               | Severe chest pain | Abnormal (not described)                                                   | Regional wall motion abnormalities, evidence of LGE, and elevated native T1 and T2 | No                              | No                                                                                      |
| Shere et al. 2021 [14]      | 3               | 67       | 24          | 4                                               | Chest pain         | ST-elevation                                                               | Epicardial oedema, epicardial fibrosis, regional interstitial expansion        | No                              | No                                                                                      |
| Jain et al. 2021 [15]       | 63              | 92       | 16          | 2                                               | Chest pain, fever and nausea | Diffuse ST-elevation, T-wave inversion | Myocardial injury as evidenced by LGE                                      | No                              | No                                                                                      |
| Truong et al. 2021 [16]     | 139             | 91       | 16          | 2                                               | Chest pain         | Diffuse ST-elevation, non-sustained VT | LGE, myocardial oedema                                                      | Yes                             | No                                                                                      |
| D’Angelo et al. 2021 [17]   | 1               | 100      | 30          | 3                                               | Chest pain, nausea, profuse sweating | Subtle ST-segment elevation suggestive of potential myocardial injury or pericarditis in V2-V4 and nonspecific T-wave changes in V5 and V6 | Subepicardial enhancement of the myocardium, enhancement of pericardium was also seen | Yes                             | No                                                                                      |
| Perez et al. 2021 [18]      | 7               | 86       | 25          | 3                                               | Chest pain, dyspnoea and fatigue | ST-segment changes                                                        | Myocardial delayed enhancement                                                | Yes                             | Hypertension, obesity, obstructive sleep apnea, smoking and dyslipidemias             |
| Multikumar et al. 2021 [19] | 1               | 100      | 52          | 3                                               | Chest pain          | Sinus rhythm with left axis deviation and incomplete right bundle-branch block without ST- or T-wave changes | Midmyocardial and subepicardial linear and modular LGE in the inferoseptal, inferolateral, anterolateral, and apical walls | Yes                             | Hypertension, hypercholesterolemia, obstructive sleep apnea                           |
| Naveet et al.               |                 |          |             |                                                 |                    |                                                                             | Myocardial oedema and gadolinium                                              |                                 |                                                                                      |
| Year | Authors | Gender | Age | Sus. | Chest Pain / Symptoms | ECG Findings | Other Findings | 1st Record | 2nd Record |
|------|---------|--------|-----|------|-----------------------|--------------|---------------|------------|------------|
| 2021 | Naghashzadeh et al. [21] | 1 M | 100 | 2 | Chest pain | ST-segment elevation | Not done acutely | Yes | Yes |
| 2021 | Gautam et al. [22] | 1 M | 100 | 66 | Chest pain and diaphoresis | 1 mm ST-elevation on anterior leads. | Moderately impaired left ventricular systolic function with LV ejection fraction of 44%, presence of myocardial and epicardial enhancement at a mid-ventricular level along the anterior septum extending to base, sparing the subendocardium | Yes | Hyperension, type II diabetes mellitus, and hyperlipidemia |
| 2021 | Parmar et al. [23] | 4 M | 75 | 22 | Chest pain and diaphoresis | AV block, diffuse ST-elevation | Mild LGE is seen in the inferolateral region in the pericardium | Yes | No |
| 2021 | Watkins et al. [24] | 1 M | 100 | 20 | Chest pain and mild shortness of breathing | Diffuse concave ST-segment elevations with PR depressions | Positive for myocarditis; details not included | Yes | No |
| 2021 | Łaźniak-Pfajfer et al. [25] | 3 M | 100 | 17 | Chest pain and shortness of breathing | Negative T-waves in the inferior leads and flat T waves in V6 in one of the patients | LGE, pericardial effusion | No | No |
| 2021 | King et al. [26] | 4 M | 100 | 23 | Chest pain | Down-sloping PR depressions and diffuse ST-elevations | Delayed gadolinium enhancement suggestive of fibrosis involving the mid to apical anterolateral wall segments | No | No |
| 2021 | Fosch et al. [27] | 1 M | 100 | 24 | Chest pain and fever | Concave ST-elevation | Oedema in basal. LGE showed patchy, subepicardial enhancement | Yes | Yes |
| 2021 | Schmitt et al. [28] | 1 M | 100 | 19 | Chest pain | Persistent ST-elevation without reciprocal depression | LGE sequences identifying a lateral subepicardial enhancement | No | No |
| 2021 | Shumkova et al. [29] | 1 M | 100 | 23 | Chest pain, shortness of breathing and fever | ST-elevation in inferior and V4-V6 | T2-weighted images showed increased signal intensity in basal segments indicating interstitial oedema | Yes | No |
| 2021 | Cui et al. [30] | 2 M | 50 | 07 | Chest tightness, fever, chills, tiredness and chest pain | RBBB, ST-elevation on anterior leads with third-degree atrioventricular block | LGE imaging demonstrates myocardial necrosis in the middle ventricular septum with thinning of the lateral wall and formation of fibrosis, myocardial oedema | Yes | No |
| 2021 | Azir et al. [31] | 1 M | 100 | 17 | Chest pain and fever | Sub-1 mm lateral ST elevations with sub-1 mm depression in lead III | Diffuse, subepicardial delayed gadolinium enhancement of the anterior and lateral wall of the left ventricle, with corresponding heterogeneous T1 signal prolongation and increased short tau inversion recovery signal | Yes | No |
| 2021 | Marsur et al. [32] | 2 M | 50 | 21 | Chest pain and fever | Mild diffuse concave ST elevation without reciprocal changes | Subepicardial enhancement in the inferolateral wall at the base | No | No |
| 2021 | Riedel et al. [33] | 1 M | 100 | 47 | Chest pain, fever and associated pneumonia attacks | Sinus tachycardia and left ventricular overload | Hypokinetic LV and RV in cardiac MRI, bialtrial dilatation, mitral and tricuspid insufficiency, and late enhancement of non-ischemic aspect | No | Type II diabetes |
| 2021 | Sciaccaluga et al. [34] | 2 M | 100 | 20 | Fever and chest pain | Sinus rhythm, normal atrioventricular conduction, incomplete right bundle branch block | Myocardial oedema and LGE with subepicardial pattern | Yes | No |
| 2022 | Murakami et al. | 2 M | 100 | 30 | Chest pain | ST-elevation in multiple | LGE showed a subepicardial lesion in anterolateral segments at the left ventricular mid- | Yes | No |
| Study et al.  | Year | Age (mean) | Sex (%) | Symptom onset after vaccination | Days to hospitalization after vaccination | Symptoms (%) | Highest reported value of troponin |
|--------------|------|------------|---------|---------------------------------|-------------------------------------------|--------------|----------------------------------|
| Kerkhove et al. | 2022 | 22 | 94% | Median - 3 days (range -- 1–30 days) | Median - 3 days (range -- 1–25 days) | Fever - 170 (62%) | Troponin (24) - median -- 8.161 ng/mL (range -- 0.37 – 44.8 ng/mL) |
| Tailor et al. | 2021 | 100 | 44% | Median - 3 days (range -- 1–30 days) | Median - 3 days (range -- 1–25 days) | Myalgia/generalized body ache - 16 (6%) | Troponin (19) - median -- 1.332 ng/mL (range -- 0.39 – 3.72 ng/mL) |
| Ohnishi et al. | 2021 | 26 | 1% | Median - 3 days (range -- 1–30 days) | Median - 3 days (range -- 1–25 days) | Chills/rigors - 15 (5%) | High sensitivity troponin (9) - median -- 0.70 ng/mL (range -- 0.18 – 15.34 ng/mL) |
| Kawakami et al. | 2022 | 0 | 45% | Median - 3 days (range -- 1–30 days) | Median - 3 days (range -- 1–25 days) | Dyspnea/sob - 13 (5%) | High sensitivity troponin (4) - median -- 6.90 ng/mL (range -- 6.77 – 14.35 ng/mL) |
|               |      | 45 | 7%  | Median - 3 days (range -- 1–30 days) | Median - 3 days (range -- 1–25 days) | Fatigue - 8 (3%) | Troponin reported as multiple of upper limit of normal (8). Median -- 192.5 (range -- 29 – 1433). |
|               |      | 45 | 7%  | Median - 3 days (range -- 1–30 days) | Median - 3 days (range -- 1–25 days) | Troponin not specified (1) - value 0.11 ng/mL | Troponin not specified (1) - value 0.11 ng/mL |
Most of the patients who presented with chest pain were later diagnosed with myocarditis. Out of 276 patients, the mean age was 22 years, ranging from ages 17 to 66. Quite significantly, the vast majority of patients who developed myocarditis were male - 262 out of 276 (94%) - suggesting that the male population was more susceptible to having myocarditis. Additionally, the majority of patients (262) developed myocarditis symptoms after the second dose of their COVID-19 vaccination. The median number of days between vaccination and admission to hospital was three days. In terms of symptoms, all 276 patients developed chest pain (100%). More than half had fevers - 170 (62%). Other symptoms reported were chills (5%), dyspnoea (5%), and fatigue (3%).

Most patients had ECG abnormalities and about 260 (94%) patients had ST-segment elevation. Most patients had elevated inflammatory markers such as troponin I, C-reactive protein (CRP), and brain natriuretic peptide (BNP) levels. The peak troponin-I level was 162.275 ng/ml ± 754.804 ng/mL. CRP level was 26.43 mg/L ± 31.98 mg/L and the BNP level was 51.31 pg/ml ± 25.64 pg/ml (Table 2).

COVID-19 PCR tests were negative in all these patients. Most patients had echocardiography and the
estimated ejection fraction on echocardiography was about 51% of these patients. Only 22 patients underwent coronary angiography following ECG and echocardiography. Of these, 20 patients had completely normal coronary arteries and only two patients had mild coronary artery irregularities. Most patients had the diagnosis of myocarditis confirmed with cardiac MRI, which showed cardiac wall oedema on gadolinium enhancement with signs of hyperaemia or fibrosis. 32 patients (80%) from a total of 40 patients had myocardial wall oedema on gadolinium enhancement on CMR scans.

The association between the type of vaccine and the dose of vaccine administered for individual studies is shown in Table 4. Most COVID-19 vaccine-induced myocarditis cases were reported with the Pfizer vaccine, followed by the Moderna vaccine (Figure 2 and Table 5). Figure 3 and Table 6 show the incidence of COVID 19 myocarditis with the number of vaccine doses and 250 cases were reported after the second dose of COVID 19 vaccination.

| Serial number | Study author        | Type of vaccine                                                                 | Myocarditis after first vaccine dose | Myocarditis after second vaccine dose | Myocarditis after third vaccine dose |
|---------------|---------------------|----------------------------------------------------------------------------------|-------------------------------------|--------------------------------------|-------------------------------------|
| 1             | Montgomery et al. 2021 [11] | mRNA BNT162b Pfizer 7 (30%) mRNA-1273 Moderna 16 (70%)                        | 3 (13%)                            | 20 (87%)                             | 0 (0%)                             |
| 2             | Garcia et al. 2021 [12] | mRNA BNT162b Pfizer 1 (100%)                                                      | 0 (0%)                             | 1 (100%)                            | 0 (0%)                             |
| 3             | Kim et al. 2021 [13]   | mRNA-1273 Moderna 2 (50%) mRNA BNT162b Pfizer 2 (50%)                          | 0 (0%)                             | 4 (100%)                            | 0 (0%)                             |
| 4             | Shaw et al. 2021 [14]  | mRNA BNT162b Pfizer 3 (75%) mRNA-1273 Moderna 1 (25%)                          | 2 (50%)                            | 2 (50%)                             | 0 (0%)                             |
| 5             | Jain et al. 2021 [15]  | mRNA BNT162b Pfizer 59 (94%) mRNA-1273 Moderna 4 (6%)                          | 1 (1.6%)                           | 62 (98.4%)                          | 0 (0%)                             |
| 6             | Truong et al. 2021 [16] | mRNA BNT162b Pfizer 131 (94.2%) mRNA-1273 Moderna 5 (3.6%) Johnson & Johnson 1 (0.7%) Unknown 2 (0.4%) | 12 (8.6%)                         | 128 (91.4%)                         | 0 (0%)                             |
| 7             | D’Angelo et al. 2021 [17] | mRNA BNT162b Pfizer 1 (100%)                                                      | 0 (0%)                             | 1 (100%)                            | 0 (0%)                             |
| 8             | Perez et al. 2021 [18] | mRNA BNT162b Pfizer 3 (42%) mRNA-1273 Moderna 4 (57%)                          | 1 (14.3%)                           | 6 (85.7%)                            | 0 (0%)                             |
| 9             | Muthukumar et al. 2021 [19] | mRNA-1273 Moderna 1 (100%)                                                      | 0 (0%)                             | 1 (100%)                            | 0 (0%)                             |
| 10            | Nevet et al. 2021 [20] | mRNA BNT162b Pfizer 3 (100%)                                                     | 0 (0%)                             | 3 (100%)                            | 0 (0%)                             |
| 11            | Naghashzadeh et al. 2022 [21] | rAd26 and rAd5 vector-based Sputnik V 1 (100%)                                    | 0 (0%)                             | 1 (100%)                            | 0 (0%)                             |
| 12            | Gautam et al. 2021 [22] | mRNA BNT162b Pfizer 1 (100%)                                                     | 0 (0%)                             | 1 (100%)                            | 0 (0%)                             |
| 13            | Parmar et al. 2021 [23] | mRNA-1273 Moderna 4 (100%)                                                       | 1 (25%)                             | 3 (75%)                             | 0 (0%)                             |
| 14            | Watkins et al. 2021 [24] | mRNA BNT162b Pfizer 1 (100%)                                                     | 0 (0%)                             | 1 (100%)                            | 0 (0%)                             |
| 15            | Łaźniak-Pfajfer et al. 2021 [25] | mRNA BNT162b Pfizer 3 (100%)                                                     | 2 (66.6%)                           | 1 (33.3%)                           | 0 (0%)                             |
| 16            | King et al. 2021 [26] | mRNA-1273 Moderna 3 (75%) mRNA BNT162b Pfizer 1 (25%)                          | 0 (0%)                             | 4 (100%)                            | 0 (0%)                             |
| 17            | Fosch et al. 2022 [27] | mRNA BNT162b Pfizer 1 (100%)                                                     | 0 (0%)                             | 0 (0%)                             | 1 (100%)                           |
| 18            | Schmitt et al. 2021 [28] | mRNA BNT162b Pfizer 1 (100%)                                                     | 0 (0%)                             | 1 (100%)                            | 0 (0%)                             |
|   | Study            | Vaccine Type          | Incidence 1 (100%) | Incidence 2 (100%) | Incidence 0 (0%) |
|---|------------------|-----------------------|---------------------|---------------------|------------------|
| 19 | Shumkova et al. 2021 [29] | mRNA BNT162b2 Pfizer 1 | 1 (100%)            | 0 (0%)              | 0 (0%)           |
| 20 | Cui et al. 2021 [30] | Sinopharm Vero-Cell 2 | 2 (100%)            | 0 (0%)              | 0 (0%)           |
| 21 | Azir et al. 2021 [31] | mRNA BNT162b2 Pfizer 1 | 0 (0%)              | 1 (100%)            | 0 (0%)           |
| 22 | Mansour et al. 2021 [32] | mRNA-1273 Moderna 2  | 0 (0%)              | 2 (100%)            | 0 (0%)           |
| 23 | Riedel et al. 2021 [33] | Sinovac 1             | 0 (0%)              | 1 (100%)            | 0 (0%)           |
| 24 | Sciaccaluga et al. 2022 [34] | mRNA-1273 Moderna 2 | 0 (0%)              | 2 (100%)            | 0 (0%)           |
| 25 | Murakami et al. 2022 [35] | mRNA BNT162b2 Pfizer 2 | 1 (50%)             | 1 (50%)             | 0 (0%)           |
| 26 | Kerkhove et al. 2022 [36] | ChAdOX1 nCoV-19 Astra Zeneca 1 | 0 (0%) | 1 (100%) | 0 (0%) |
| 27 | Tailor et al. 2021 [37] | mRNA-1273 Moderna 1  | 0 (0%)              | 1 (100%)            | 0 (0%)           |
| 28 | Ohnishi et al. 2021 [38] | mRNA BNT162b2 Pfizer 1 | 0 (0%)              | 1 (100%)            | 0 (0%)           |
| 29 | Kawakami et al. 2022 [39] | mRNA-1273 Moderna 1  | 0 (0%)              | 1 (100%)            | 0 (0%)           |

**TABLE 4: Incidence of myocarditis and its relation to COVID-19 vaccine dosage**

![Myocarditis Cases by Vaccine sub-type](image-url)  

**FIGURE 2: Myocarditis cases by vaccine sub-type**
| vector         | mRNA BNT162b2 Pfizer | mRNA-1273 Moderna | Vector ChAdOx1 nCoV-19 AstraZeneca | Vector Johnson & Johnson | Vector Sputnik V | Whole virus Sinopharm | Whole virus Sinovac | Unknown |
|---------------|----------------------|-------------------|-----------------------------------|-------------------------|-----------------|-----------------------|---------------------|---------|
| Cases         | 223                  | 46                | 1                                 | 1                       | 1               | 2                     | 1                   | 2       |

**TABLE 5: Myocarditis cases by the number of vaccine doses**

Myocarditis Cases by number of Vaccine Doses

![Chart showing myocarditis cases by vaccine dose](chart.png)

**FIGURE 3: Myocarditis cases by the number of vaccine doses**

| Vaccine Dose     | Number of Cases |
|------------------|-----------------|
| First dose       | 26 (9.4%)       |
| Second dose      | 250 (90%)       |
| Third dose       | 1 (0.4%)        |

**TABLE 6: COVID-19 vaccine-induced myocarditis cases based on vaccine doses**

In terms of treatment options, 36 patients (13%) received NSAIDs, 21 patients (8%) received colchicine, nine patients (3%) received steroids and six patients (2%) received IVIG. There was no mortality reported in all 276 patients who were all discharged home.

**Discussion**

COVID-19 vaccine-related myocarditis has been reported for the past two years, mainly in case reports and only a few systematic reviews have been undertaken on this topic [40-42]. This was more commonly seen in younger males after the second dose of the mRNA vaccine. Myocarditis presentations can vary and patients can present with a range of symptoms from asymptomatic to heart failure requiring a heart transplant, or lethal heart arrhythmias and sudden cardiac death in most severe cases. Fortunately, most myocarditis cases associated with mRNA vaccines are mild in nature and do not have serious complications and require only a few days of hospital admission. According to the US Centre for Disease Control director Dr Rochelle Walensky, if one million children are fully immunized against COVID-19, 30-40 children may get mild myocarditis, however, this will prevent 8000 cases of COVID-19, 200 hospital admissions, 50 intensive care unit (ICU) stays and one death in this age group [43].

One major concerning complication of myocarditis is heart failure which could be heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF). Clinically, myocarditis has three possible phenotypes which include acute myocarditis, fulminating myocarditis, and chronic active myocarditis [44,45]. Acute myocarditis patients usually have mild symptoms which occur following a gastrointestinal or upper respiratory tract infection and patients have complete recovery in most cases.
According to the Marburg Myocarditis Registry, 2.5% of patients out of 1000 biopsy-confirmed myocarditis patients presented with the fulminant phenotype; however, this has been reported to be up to 30% in other studies [46]. These patients usually have more severe symptoms compared to acute myocarditis and may require vasopressor support due to severe myocardial inflammation. It is more common in patients with underlying autoimmune conditions such as systemic lupus erythematosus (SLE), scleroderma, Sjögren’s, or those on immunosuppressive therapy [39]. Based on histology, this type of myocarditis may be lymphocytic, eosinophilic, or giant cell and an immune checkpoint inhibitor (ICI)-induced myocarditis is usually of fulminant type. The final type of myocarditis is chronic active myocarditis in which there is constant low-grade inflammation of the myocardium after initial acute myocarditis and usually leads to intramural and/or epicardial scarring progressing to dilated cardiomyopathy (DCM) [47].

The vast majority of patients who developed myocarditis after vaccination were males. This is consistent with another study done retrospectively of 40 COVID-19 vaccine-related myocarditis patients, out of whom 90% were male [48]. Additionally, the vast majority of patients who developed myocarditis did so after the second dose of their vaccine. This suggests the likelihood that the myocarditis could be ‘hypersensitivity myocarditis’, which is a delayed, type IV type, drug-induced reaction with eosinophilic inflammation and a T helper cell type 2 response [49], with the first dose acting as a sensitizing exposure to the immunogenic trigger.

The underlying pathophysiology of vaccine-induced myocarditis remains unclear. One possible mechanism is molecular mimicry; the cardiac self-antigens being similar in structure to the spike protein of SARS-CoV-2 and so being targeted by the individual’s own antibodies, leading to cardiac inflammation [50]. These individuals might be more prone to such a response due to their own immunogenetic background, leading to hyperimmunity following vaccination. Another theory, driven by the fact that males seem to be more susceptible to myocarditis following coronavirus vaccination than women, is that testosterone and oestrogen levels mitigate an individual’s immune response. Oestrogen inhibits pro-inflammatory T cells, leading to a ‘softer’ immune response while testosterone promotes T helper 1 cell-type response, leading to hyperimmunity [49,50].

The majority of patients diagnosed with myocarditis underwent cardiac MRI, which is the gold standard imaging for the diagnosis of myocarditis according to the European Society of Cardiology [51]. Not only does it provide accurate information about the degree of inflammation, cardiac function and viability, it is also effective in determining prognosis [51,52]. Additionally, it is an excellent imaging modality in patients who have non-diagnostic echocardiograms due to limitations such as body habitus. The management of myocarditis included non-steroidal anti-inflammatory drugs (NSAIDs), steroids, intravenous immunoglobulin (IVIG) and colchicine. Although there are no randomized clinical trials to establish the best treatment choice for vaccine-induced myocarditis [53], it is prudent to manage the condition based on its severity. For example, NSAIDs may relieve chest pain but might exacerbate heart failure through sodium retention, whereas steroids or IVIG might be more strongly indicated in patients with myocarditis-induced arrhythmias.

It is important to mention that the COVID-19 infection is also associated with myocarditis and the associated risk is higher than the mRNA vaccine-associated risk. Some studies note a mortality rate of 14% in patients with COVID-19 infection-induced myocarditis [54]. It is important to note such statistics when discussing the risks vs benefits of vaccination with patients, in order to help them make informed decisions. Table 7 shows the data for the total number of various COVID-19 vaccines administered and their reported side effects across the European Union and the European economic area (EEA) [55]. In a systemic review by Matta et al., about 93% of patients were male and the median age of onset was 21 years and almost 89% of patients developed myocarditis after the second dose [56].
### TABLE 7: Total doses of various COVID-19 vaccines administered in EU and EEA and reported side effects

| Vaccine type       | Total number of vaccines administered | Reported side effects |
|--------------------|---------------------------------------|-----------------------|
| BioNTech and Pfizer| 627,000,000                           | 743,735               |
| AstraZeneca        | 69,000,000                            | 276,697               |
| Moderna            | 155,000,000                           | 206,920               |
| Janssen            | 19,400,000                            | 48,410                |
| Novavax            | 178,000                               | 294                   |

EU: European Union; EEA: European Economic Area [56].

### Limitations

Most articles reviewed in this systematic review were case series comprising multiple case reports of myocarditis following vaccination against coronavirus. Long-term studies that investigate the prognosis of patients who develop myocarditis need to be conducted. Additionally, the studies featured in this systematic review have highlighted cases that have been severe enough to present to medical services, whereas cases of myocarditis that have been milder or patients who have not sought medical attention have not been included meaning that there may be under-representation of myocarditis cases following coronavirus vaccination. This includes patients in developing countries who might not have the means for investigations such as cardiac MRI and might be misdiagnosed as simply having heart failure or ischaemic heart disease.

This systematic review has been appraised using the Critical Appraisal Skills Programme (CASP) tool present in the appendix section [57].

### Conclusions

Post-vaccination myocarditis is predominantly seen in young male patients in their early 20s with an average age of 21 years. Most patients with vaccine-induced myocarditis present within a few days following the second dose of COVID-19 vaccines. The most common presenting symptom is chest pain followed by fever and myalgia or general body ache. The electrocardiogram is abnormal in most patients and may show either ST-segment elevation or T waves inversion or non-specific ST-segment changes. Most patients have elevated troponin I and raised inflammatory markers on blood tests and cardiac magnetic resonance imaging shows late gadolinium enhancement which indicate myocardial necrosis or fibrosis in these patients. The diagnosis of vaccine-induced myocarditis is initially made based on the presenting history of chest pain following recent administration of mRNA vaccination, elevated troponin, abnormal electrocardiogram findings and characteristic findings on cardiac MRI. Although the prognosis is good as all the reported patients recovered and were discharged home, further research is needed to understand the pathophysiology of post-vaccination myocarditis and to improve the standard of care for these patients.

### Appendices

This review has been appraised using the Critical Appraisal Skills Programme (CASP) tool [57] (Table 8).

### Section A: Are the results of the review valid?

- **Did the review address a clearly focused question?**
  - Yes ✓

  **HINT:** An issue can be 'focused' in terms of • the population studied • the intervention given • the outcome considered

- **Comments:** Sufficient evidence to suggest that there is a temporal relationship between COVID-19 vaccines and myocarditis
**Did the authors look for the right type of papers?**

- **Yes ✓**
- **Can't Tell**
- **No**

**Comments:** No RCT's performed due to the nature of myocarditis occurring as a side-effect of COVID-19 vaccinations, which is why case series and reports were predominantly used.

**Is it worth continuing?**

- **Yes ✓**
- **Can't Tell**
- **No**

**Comments:** Non-English studies were not used.

**4. Did the review's authors do enough to assess quality of the included studies?**

- **Yes ✓**
- **Can't Tell**
- **No**

**Comments:** Inclusion and Exclusion criteria were used – only studies in which Covid-19 vaccines were administered and myocarditis was definitively diagnosed were used.

**5. If the results of the review have been combined, was it reasonable to do so?**

- **Yes ✓**
- **Can't Tell**
- **No**

**Comments:**

**Section B: What are the results?**

**6. What are the overall results of the review?**

- **Yes ✓**
- **Can't Tell**
- **No**

**Comments:** There is a temporal relationship between Covid-19 vaccines and myocarditis – it is quite likely that Covid-19 vaccination causes myocarditis, although further studies can be done to prove this.

**7. How precise are the results?**

- **Yes ✓**
- **Can't Tell**
- **No**

**Comments:** Due to the lack of RCT's performed on this subject matter, it is difficult to comment on exact precision.
### Section C: Will the results help locally?

| Question                                                                 | Answer | HINT                                                                 | Comments |
|--------------------------------------------------------------------------|--------|----------------------------------------------------------------------|----------|
| 8. Can the results be applied to the local population?                   | Yes    | HINT: Consider whether the patients covered by the review could be sufficiently different to your population to cause concern your local setting is likely to differ much from that of the review | Same vaccines are used in local vaccination program that were used in the studies included in the systematic review |
| 9. Were all important outcomes considered?                               | Yes    | HINT: Consider whether there is other information you would like to have seen | Long-term studies on these patients are yet to be done to see the long-term effects of myocarditis |
| 10. Are the benefits worth the harms and costs?                          | Yes    | HINT: Consider even if this is not addressed by the review, what do you think? | Covid-19 itself causes myocarditis to a higher degree than vaccination does. Hence vaccination outweighs the harms and costs |

### TABLE 8: Critical Appraisal Skills Programme tool

**Additional Information**

**Disclosures**

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Lampejo T, Durkin SM, Bhatt N, Guttmann O: Acute myocarditis: aetiology, diagnosis and management. Clin Med (Lond). 2021, 21:e505-10. 10.7861/clinmed.2021-0121
2. Imazio M, Gaita F, LeWinter M: Evaluation and treatment of pericarditis: a systematic review. JAMA. 2015, 314:1498-506. 10.1001/jama.2015.12765
3. Checcucci E, Piramide F, Pecoraro A, et al.: The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans. Panminerva Med. 2022, 64:72-9. 10.23736/S0031-0808.20.03958-0
4. Tschöpe C, Ammirati E, Bozkurt B, et al.: Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021, 18:169-193. 10.1038/s41569-020-00435-x
5. Sen-Chowdhry S, Syrris P, Prasad SK, et al.: Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008, 52:2175-87. 10.1016/j.jacc.2008.09.019
6. Cafferio AL, Calabrrese F, Angelini A, et al.: A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetio-pathogenetic features at diagnosis. Eur Heart J. 2007, 28:1526–33. 10.1093/eurheartj/ehm076

7. Global Burden of Disease Study 2013 Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015, 386:743-800. 10.1016/S0140-6736(15)60692-4

8. Lota AS, Halliday B, Tayau Y, et al.: Abstract 11465: epidemiological trends and outcomes of acute myocarditis in the national health service of England. Circulation. 2019, 140:11463.

9. Fazloollahi A, Zahnmatyar M, Noori M, et al.: Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol. 2022, 32:2251B. 10.1002/rmv.2318

10. Ling RR, Ramanathan K, Tan FL, Tai BC, Somani J, Fischer D, MacLaren G: Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir Med. 2022, 10:679-88. 10.1016/S2215-2600(22)00059-5

11. Montgomery J, Ryan M, Engler R, et al.: Myocarditis following immunization with mRNA COVID-19 vaccines in members of the us military. JAMA Cardiol. 2021, 6:1202-6. 10.1001/jamacardio.2021.2835

12. Bautista García J, Peña Ortega P, Bonilla Fernández JA, Cárdenes Leín A, Ramírez Burgos L, Caballero Dorta E: Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev Esp Cardiol (Engl Ed). 2021, 74:812-4. 10.1016/j.rec.2021.04.005

13. Kim HW, Jenista ER, Wendell DC, et al.: Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol. 2021, 6:1196-201. 10.1001/jamacardio.2021.2828

14. Shaw KE, Cavalcante JL, Han BK, Gózal M: Possible association between COVID-19 vaccine and myocarditis: clinical and CMR findings. JACC Cardiovasc Imaging. 2021, 14:1856-61. 10.1016/j.jcmg.2021.06.002

15. Jain SS, Steeke JM, Fonseca B, et al.: COVID-19 vaccination-associated myocarditis in adolescents. Pediatrics. 2021, 148:10.1542/peds.2021-053427

16. Truong DT, Dionne A, Muniz JC, et al.: Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis in 100 vaccinated patients. Circulation. 2022, 145:345-56. 10.1161/CIRCULATIONAHA.121.056583

17. D’Angelo T, Cattafi A, Carei ML, et al.: Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced myocarditis? Can J Cardiol. 2021, 37:1665-7. 10.1016/j.cjca.2021.05.010

18. Perez, Levy ER, Joshi AY, et al.: Myocarditis following COVID-19 mRNA vaccine: a case series and incidence rate determination [IN PRESS]. Clin Infect Dis. 2021, 10.1093/cid/ciab926

19. Mathukumar A, Narasimhan M, Li QZ, et al.: In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine. Circulation. 2021, 144:487-98. 10.1161/CIRCULATIONAHA.121.056038

20. Nevet A: Acute myocarditis associated with anti-COVID-19 vaccination. Clin Exp Vaccine Res. 2021, 10:196-7. 10.7774/cevr.2021.10.2.196

21. Naghashzadeh F, Shafaghi S, Dorudinia A, et al.: Myocarditis following rAd26 and rAd5 vector-based COVID-19 vaccine: case report. ESC Heart Fail. 2022, 9:1485-6. 10.1002/ehf2.13821

22. Gautam N, Saluja P, Fudim M, Jambhekar K, Pandey T, Al Aref S: A late presentation of COVID-19 vaccine-induced myocarditis. Cureus. 2021, 15:e17890. 10.7759/cureus.17890

23. Parmar K, Meekraksakit P, Del Río-Pertuz G, et al.: Myocarditis following COVID-19 mRNA vaccination. Proc (Bayl Univ Med Cent). 2022, 35:209-15. 10.1089/pnum.2021.190743

24. Watkins K, Griffin G, Septaric K, Simon EL: Myocarditis following BNT162b2 vaccination in a healthy male. Am J Emerg Med. 2021, 50:815.e1-2. 10.1016/j.ajem.2021.06.051

25. Łaziński-Pfajfer A, Surmacz R, Rajewska-Tabor J, Pyda M, Lesiak M, Bobkowski W: Myocarditis associated with COVID-19 vaccination in three male teenagers. Pol Arch Intern Med. 2022, 152:16160. 10.20452/pami.16160

26. King WW, Petersen MR, Matar RM, Budweg JB, Cuervo Pardo L, Petersen JW: Acute myocarditis after COVID-19 vaccination: A late presentation of COVID-19 myocarditis. J Emerg Med. 2021, 61:e129-32. 10.1016/j.jemermed.2021.09.017

27. Schmitt P, Demoulin R, Peyot R, et al.: Myocarditis following COVID-19 vaccination. Clin Med Interne. 2021, 42:797-800. 10.1016/j.clinmed.2021.10.005

28. Shumková M, Vassilev D, Karamfillov K, Ivanova R, Stoyanova K, Yaneva-Sirátková T, Gil R: Acute myocarditis associated with the Pfizer/BioNTech vaccine. Kardiol Pol. 2021, 79:1292-3. 10.33963/ KP.a2021.0095

29. Cui G, Li R, Zhao C, Wang DW: Casereport: COVID-19 vaccination associated fulminant myocarditis. Front Cardiovasc Med. 2021, 8:769616. 10.3389/fcvm.2021.769616

30. Azir M, Inman B, Webb J, Tannenbaum L: STEMi Mimic: focal myocarditis in an adolescent patient after mRNA COVID-19 Vaccine. J Emerg Med. 2021, 61:e129-32. 10.1016/j.ijem.2021.05.017

31. Mansour J, Short RG, Bhulla S, Woodward PK, Verma A, Robinson X, Raptis DA: Acute myocarditis following the second dose of the mRNA COVID-19 vaccine: a report of two cases. Clin Imaging. 2021, 78:247-9. 10.1016/j.clinimag.2021.06.019

32. Riedel PG, Sakai VF, Toniaso SC, et al.: Heart failure secondary to myocarditis after SARS-CoV-2 reinfecion: a case report. Int J Infect Dis. 2021, 115:175-7. 10.1016/j.ijid.2021.05.031

33. Sciaccaluga C, D’Ascenzi F, Cannell M, et al.: Case report: two case reports of acute myopericarditis after mRNA COVID-19 vaccine. Front Cardiovasc Med. 2022, 9:827237. 10.3389/fcvm.2022.827237

34. Murakami Y, Shinohara M, Oka Y, et al.: Myocarditis following a COVID-19 messenger RNA vaccination: a Japanese case series. Intern Med. 2022, 61:501-5. 10.2169/internalmedicine.8731-21

35. Van Kerkhove O, Renders F, Leys M: A case of myocarditis following ChAdOx1 nCoV-19 vaccination. Acta Cardiol. 2022, 1-3. 10.1080/00015385.2022.2040825

36. Tailor PD, Feighery AM, El-Sabawi B, Prasad A: Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep. 2021, 5:ytab319. 10.1093/ehjcr/ytab319
38. Ohnishi M, Tanaka Y, Nishida S, Sugimoto T: Case report of acute myocarditis after administration of coronavirus disease 2019 vaccine in Japan. Eur Heart J Case Rep. 2022, 6:ytab534. 10.1093/ehjcr/ytab534

39. Kawakami T, Yahagi K, Sekiguchi M, et al.: Acute myocarditis in a patient following mRNA-1273 SARS-CoV-2 vaccination. Intern Med. 2022, 61:1371-4. 10.2169/internalmedicine.9000-21

40. Lee AS, Balakrishnan ID, Khoo CY, et al.: Myocarditis following COVID-19 vaccination: a systematic review (October 2020-October 2021). Heart Lung Circ. 2022, 31:757-65. 10.1016/j.hlc.2022.02.002

41. Fatima M, Ahmad Cheema H, Ahmed Khan MH, et al.: Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: A systematic review. Ann Med Surg (Lond). 2022, 76:103486. 10.1016/j.amsu.2022.103486

42. Goyal M, Ray I, Mascarenhas D, Kunal S, Sachdeva RA, Ish P: Myocarditis post SARS-CoV-2 vaccination: a systematic review. QJM. 2022, 10.1093/qjmed/hcac064

43. GMA: Vaccine or virus? CDC says vaccines are still safer for young people than risks of COVID. Accessed: May 25, 2022: https://www.goodmorningamerica.com/news/story/vaccine-virus-cdc-vaccines-safer-young-people-risks-78447874.

44. Blauwet LA, Cooper LT: Myocarditis. Prog Cardiovasc Dis. 2010, 52:274-88. 10.1016/j.pcad.2009.11.006

45. Sharma AN, Stulte JR, Bellamkonda N, Amsterdam EA: Fulminant myocarditis: epidemiology, pathogenesis, diagnosis, and management. Am J Cardiol. 2019, 124:1954-60. 10.1016/j.amjcard.2019.09.017

46. Hang W, Chen C, Seebert JM, Wang DW: Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes. Signal Transduct Target Ther. 2020, 5:287. 10.1038/s41392-020-00360-y

47. Ammirati E, Frigerio M, Adler ED, et al.: Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail. 2020, 13:e007405. 10.1161/CIRCHEARTFAILURE.120.007405

48. Chen JH, Ikwuanusi IA, Bommu VJ, Patel V, Auila H, Kauzlik V, Cheryath P: COVID-19 vaccine-related myocarditis: a descriptive study of 40 case reports. Cureus. 2022, 14:e21740. 10.7759/cureus.21740

49. Gulin D, Sikic J, Habek JC, Gulin SJ, Galic E: Hypersensitivity eosinophilic myocarditis in a patient receiving multiple drug therapy: challenges in diagnosis and defining the aetiology. Drug Saf Card Rep. 2016, 3:11. 10.1007/s40800-016-0034-8

50. Heymans S, Cooper LT: Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nat Rev Cardiol. 2022, 19:75-7. 10.1038/s41569-021-00662-w

51. McMurray JJ, Adamopoulos S, Anker SD, et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012, 33:1787-847. 10.1093/eurheartj/ehq481

52. Schwitter J, Araie AE: Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance. Eur Heart J. 2011, 32:799-809. 10.1093/eurheartj/ehq481

53. Bozkurt B, Kamat I, Hoter PJ: Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021, 144:471-84. 10.1161/CIRCULATIONAHA.121.056135

54. Hausserner W, Delosa AP, Hausserner D, Tran J, Torres-Lavoro J, Kamler J, Shah K: COVID-19 associated myocarditis: A systematic review. Am J Emerg Med. 2022, 51:50-5. 10.1016/j.ajem.2021.10.001

55. EMA: Safety of COVID-19 vaccines. (2022). Accessed: July 25, 2022: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19-treatments-

56. Matta A, Kunadhuraj R, Osman M, et al.: Clinical presentation and outcomes of myocarditis post mRNA vaccination: a meta-analysis and systematic review. Cureus. 2021, 13:e19240. 10.7759/cureus.19240

57. CASP Checklists - Critical Appraisal Skills Programme. Accessed: May 29, 2022: https://casp-net.net/casp-tools-checklists/.